Trials / Unknown
UnknownNCT02336724
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. The purpose of this study is to evaluate the efficacy and safety profile of Famitinib in patients with advanced or metastatic gastrointestinal stromal tumor who failed from imatinib therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Famitinib |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2018-12-01
- Completion
- 2019-06-01
- First posted
- 2015-01-13
- Last updated
- 2018-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02336724. Inclusion in this directory is not an endorsement.